Introduction
Gastroesophageal reflux symptoms (GERS) are highly prevalent in Western nations (1) (2) (3) (4) (5) , and may be increasing in incidence in Asia for unknown reasons (6, 7) . Similarly, the development of obesity has reached epidemic proportions in the Western world, which also remains largely unexplained (8, 9) . Obesity is important because it induces a major psychological burden (10) , and has a substantial impact on morbidity and on quality of life (11, 12) .
We have previously reported that body mass index (BMI) appeared to be an independent risk factor for the presence of heartburn and acid regurgitation in a community-based population study in the United States (13) . Others have observed similar associations in Sweden but there have also been contradictory reports (14, 15) . We have also observed an association between obesity and symptoms of diarrhea in population-based studies from the USA, Australia, and in a New Zealand birth cohort of young adults (16) (17) (18) . However, these studies were all in un-investigated subjects, and the relationship between BMI and unexplained upper and lower gastrointestinal symptoms remains to be clarified.
A number of drugs have been reported to lower esophageal sphincter pressure (19) (20) (21) (22) (23) and an association between use of such drugs and an increased risk of esophageal adenocarcinoma has also been observed (24) . However, population based studies that includes endoscopic data have not investigated how important medications are in causing esophagitis, and whether their use mediates the possible association between BMI and GERS.
In this study, we aimed to evaluate the relationship between measured BMI and specific GI symptoms in a community-based population that was being evaluated by esophagogastroduodenoscopy. We hypothesized that the association of obesity with symptoms of GERS would be largely explained by underlying esophagitis or by medications that could potentially aggravate gastroesophageal reflux.
Materials and Methods

Setting
The setting consisted of two neighboring communities in Northern Sweden, Kalix and Haparanda, with 18 408 and 10 580 inhabitants (as of December 1998); 78 % lived in city populated areas during the year 2000, compared to the Swedish national average of 84%. The distribution of age and gender was similar to the national average in Sweden in both communities, although unemployment status, income, and the proportion with a higher education were slightly lower.
Sampling
By using the computerized national population register, covering all citizens in the two communities by date of birth order, a representative sample was generated. Every seventh adult (n=3000) from the target population (20-80 years of age, n=21 610 in September 1998) was drawn, a procedure equivalent to random sampling. The sampled subjects were then, by a computerized process, given an identity number (ID) (ID 1-3000) in random order.
Study design and logistics
The study population (n=3000) was contacted by mail and was invited to take part; this invitation included a validated questionnaire, the Abdominal Symptom Questionnaire (see below) to be returned by mail. Up to two remainders were applied when necessary; 140 subjects were unavailable at the time for invitation (21 dead; 38 migrated or questionnaire returned by relatives; 17 mentally retarded or having dementia; and 76 for other reasons). Thus, 2860 of the original study population were eligible for inclusion. The responders were invited to a visit in the clinic in ID order, starting with the lowest available ID. The subjects reported the absence/presence of gastrointestinal symptoms using the ASQ questionnaire at the visit as described below. The study population was divided into five parts in ascending order for logistic reasons, ID 1-600, 601-1200 and so forth, and the first subset of study subjects was approached with the mailed ASQ questionnaire in December 1998. The study was approved by the Umeå University ethics committee and conducted in accordance with the revised Declaration of Helsinki.
Assessments
Abdominal Symptom Questionnaire (ASQ). This self-administered questionnaire assesses symptoms from the upper and lower part of the abdomen and has been validated in Sweden (25, 26) . A standardized procedure for the administration of the questionnaire at the visit was used. The ASQ includes questions describing the presence or absence (yes/no) of 27 troublesome gastrointestinal symptoms over the preceding three months. In order to better reflect the Rome I definitions of the functional gastrointestinal disorders (27) , three questions were added to the present version (28) . All participants were also asked if they had been troubled by any of 11 listed descriptors of abdominal pain (26) , in addition to symptom location (upper, center or lower abdominal, right and left flank, respectively).
Demographics and history. Demographic data were collected at the clinic visit (gender, age, weight, tobacco use and language). The subjects' level of education and number of inhabitants in their household was confirmed by questions in the ASQ at the visit at the clinic.
Definitions of symptom groups. The subjects were classified according to their symptom patterns as defined below: 1. Gastroesophageal reflux symptoms (GERS) were defined as the presence of any troublesome heartburn and/or acid regurgitation over the past three months (29, 30) . 2. Dyspepsia was defined as any troublesome pain or discomfort expressed as one or more of the 11 listed pain modalities located in the upper (epigastric) part of the abdomen, and/or nausea, early satiety or uncomfortable feeling of fullness after meal. This is consistent with the Rome II definition (except for upper abdominal bloating which was not asked about in the ASQ) (26) . 3. Irritable bowel syndrome (IBS) was defined as any of troublesome abdominal pain modalities located at any site plus concomitant bowel habit disturbances (constipation, diarrhea, or alternating constipation and diarrhea) (28) . This simple definition has been used previously and shown to produce results reasonably concordant with the Rome criteria in Sweden (28).
Epigastric pain or discomfort
Epigastric pain in the ASQ was defined as troublesome pain or discomfort expressed as one or more of the 11 listed pain or discomfort modalities indicated in the epigastric part of the abdomen only. This definition is based on the Rome I definition of dyspepsia. 5. Abdominal pain was defined as troublesome pain or discomfort expressed as one or more of the 11 listed pain or discomfort modalities indicated anywhere in the abdomen.
Response rate A total of 2122 individuals completed the postal questionnaire, which corresponds to a response rate of 74.2% after two postal reminders. These responders were representative of the local population. In order to complete the 1001 upper endoscopies, 1563 responders to the ASQ were approached; 364 declined, 74 had moved or could not be reached and 124 had medical contraindications. Thus the response rate for those eligible for investigation was 73.3%. The gender and age distribution for the 1001 subjects (488 males (48.8%)) who responded to the questionnaire at both assessments (mean age 54 yr. (21-82)) closely reflect the pattern in the Swedish population (31) . The study subjects who refused endoscopy were very similar demographically to the 1001 subjects evaluated (data not shown). Hence, a representative cohort of 1001 invited for the upper endoscopy was evaluated. Of the subjects endoscoped, 10 did not have BMI data collected, leaving 991 for analysis. The data on the prevalence of endoscopic findings in this population is presented elsewhere (32) . Esophagitis was classified according to Los Angeles classification system; detailed data on esophagitis and its associations with GERS are published elsewhere (33) .
Esophagogastroduodenoscopy (EGD)
The upper endoscopies were done by both primary and secondary care physicians in the two clinics, who provided sole medical cover in the area. The endoscopists were unaware of the symptoms of the subjects before and during endoscopy (34) .
Body mass index categories
Height and weight were measured at the endoscopy visit. The data on weight and height were used to calculate BMI; weight in kilograms divided by the square of height in meters (Kg/m (35) . Because there were relatively few subjects in the extreme obesity categories, these were all combined.
Medications
Data on medication use was recorded after the endoscopy. In addition to any acid suppressing drug, medications that were concurrently being taken that may reduce lower oesophageal sphincter pressure (nitrates, theophylline, calcium channel blockers, opiates, beta agonists, phenothiazines, tricyclic antidepressive drugs, nicotine substitutes, anticholinergics and benzodiazepines) were recorded (19) (20) (21) (22) (23) (24) .
Statistical analysis
Prevalence is shown as percentage with 95% confidence interval. We used a logistic regression analysis to assess the association between the presence of each specific GI symptom (the binary dependent variable) and BMI (entered as a categorized independent variable), adjusting for age, gender and education use. The odds ratios (OR) for a given specific symptom and 95% confidence intervals (95% CI) were computed from the coefficients (and standard errors) in the logistic regression models in which BMI was categorized as described above. Individual GI symptoms, groups of GI symptoms and other possible exposure variables were analyzed separately in different analyses by endoscopy findings. Multiple logistic regression was utilized to assess the association between BMI and GERS or separately esophagitis, adjusting for medication use as well as age, gender and education level. Linear regression analysis was applied to analyze the independent associations between BMI and possible exposure variables. 
Prevalence of obesity
The prevalence of those underweight was 0.8% (n=8); these subjects were excluded leaving 983 subjects in the subsequent analyses. The prevalence of being overweight was 46% (n=456, 95% CI 42.9, 49.1) while the prevalence of obesity was 16% (n= 162, 95% CI 14.0, 18.7). Table 1 shows the proportion of patients in each BMI category, as a whole and by gender, age groups, education levels, smoking and alcohol status. Smoking was independently associated with decreased BMI by linear regression analysis (beta coefficient -0.7) and low education was associated with increased BMI (beta coefficient 0.6); alcohol use was not significant. 
Prevalence of troublesome gastrointestinal complaints and upper endoscopy findings
At the time of endoscopy, 65.6 % of the 1001 subjects reported one or more troublesome gastrointestinal complaints on the questionnaire completed prior to endoscopy. The prevalence of major endoscopic findings by BMI category is summarized in Table 2 . Of those with esophagitis (n=155) most were grade A (n=109); 39 had grade B, 3 grade C, 2 grade D and 2 were unable to be classified. There were more endoscopic findings in obese subjects than in normal weight subjects, but the differences were not significant except for esophagitis; the prevalence of esophagitis in obesity was 26.5% (95% CI 19.7, 33.3) versus 9.3% (95% CI 6.3, 12.3) in normal weight subjects.
Relationship between BMI, GI Symptoms and other exposure factors
In the total cohort, the distribution of individual GI symptoms by BMI categories is summarized in Table 3 . 
Medication use, BMI and reflux
Use of acid reducing drugs was a significant predictor for overall GERS (OR=9.8, 95% CI 6.5, 14.7) and for following individual symptoms: heartburn (OR=6.4, 95% CI 4.5, 9.2), acid regurgitation (OR=6.2, 95% CI 4.3, 8.8) and retching (OR=3.0, 95% CI 2.1, 4.2). Drugs that potentially lower oesophageal sphincter (LES) pressure {nitrates (n=24), theophylline (n=10), calcium channel blockers (n=44), opiates (n=20), beta agonists (n=22), phenothiazines (n=2), tricyclic antidepressants (n=2), nicotine substitutes (n=0), anticholinergics (n=0) and benzodiazepines (n=2)} as a group were univariately associated with the symptom of a burning feeling rising in the chest (Carlsson-Dent question) (OR=1.8, 95% CI 1.1, 3.1) and with central chest pain (OR=1.6, 95% CI 1.0<1, 2.6), but were not significantly associated with overall GERS. Only calcium channel blockers (OR=3.0, 95% CI 1.5, 5.9) were univariately associated with the symptom of a burning feeling rising in the chest; none of the other individual drug classes were significant. LES relaxing drugs were not individually or as a group significantly associated with esophagitis. Adjusting for medication use, the association between GERS and being overweight remained significant (OR=1.4, 95% CI 1.04, 2.0) and, similarly, the association between GERS and obesity remained significant (OR=1.9, 95% CI 1.3, 3.0). The association between esophagitis and BMI did neither alter substantially adjusting for medication use (OR for overweight =1.7, 95% CI 1.1, 2.6 and OR for obesity =3.4, 95% CI 2.0, 5.8).
Discussion
We have examined the associations between GI symptoms and BMI in a population sample who were then investigated for an upper GI tract structural explanation by esophagogastroduodenoscopy. We found that reflux symptoms were linked to obesity, and specifically the presence of GERS was linked to reflux esophagitis in the population. We also observed independent associations of obesity with diarrhea type symptoms.
We have confirmed other population-based studies that have found an association between obesity and GERS (13, 14, 16, 18) . Lagergren et al. did not find any association between obesity and GERS, but their definition of reflux was based on weekly reflux symptoms for a period of no less than one year and the BMI data were obtained by self-report (15) . A study from the USA revealed a rate of reflux disease hospitalization with higher BMI (36) . We also observed a dose response effect, with the highest prevalence of GERS occurring in obesity (37) . It has been speculated that a mechanistic role (from formation of a hiatal hernia) may be important in the genesis of these symptoms; on the other hand, an abnormal diet may not be important although strong data are not available (38) . The striking result in the present study remains that the association between obesity and GERS was not evident when those with esophagitis or peptic ulcer were excluded from the analyses. These data are consistent with the results from an earlier Swedish case control study (39) .
Lagergren et al. have reported an association between medications that may relax the lower oesophageal sphincter and an increased risk for oesophageal adenocarcinoma (24) . However, we failed to find any convincing association between these drugs as a group and GERS, although we did see an association between calcium channel blockers and the symptom of a burning feeling rising in the chest. Importantly, the intake of medications did not substantially alter the association between BMI and GERS or BMI and esophagitis in the multiple logistic regression models evaluated.
Obesity was not associated with constipation in this study; others have reported concordant observations (16) (17) (18) . The finding of a link between obesity and diarrhea, however, has now been confirmed in three population-based studies, although these were all in un-investigated subjects (16) (17) (18) . Crowell et al. also observed more frequent lower gastrointestinal symptoms in overweight females attending a weight management center compared to normal weight women recruited from the community (40), although obese patients seeking treatment may not be representative of obese individuals in the community. Why does diarrhea occur in obesity rather than, as might be expected in this generally more sedentary population, constipation? We hypothesize that excess intake of poorly absorbed products causing osmotic diarrhea could explain the increased lower gastrointestinal symptoms in obesity. For example, there has been a very substantial increase in the use of corn syrup containing fructose in the USA, and excess ingestion of this could induce fructose malabsorption (41, 42) . Other mechanisms that might explain the increased bowel frequency associated with increased BMI may also include abnormal bile salt turnover because of rapid small intestinal transit or rapid gastric emptying, which has been reported in some groups of obese patients (43, 44) . Obesity was also associated with symptoms consistent with IBS in the present study. However, whether obesity is truly linked to IBS remains unclear; we did not apply the Rome II criteria for IBS as the questionnaire was not designed to assess these specifically. Others have observed a trend for more IBS symptoms in obesity but this has yet to be confirmed, and severe obesity has not been studied (45) .
Mechanisms that control food intake and energy expenditure may be dysregulated in obesity. A number of hormonal satiation factors including cholecystokinin, enterostatin and peptide YY from the gut may contribute to meal termination, and thus may influence meal size (46, 47) . Whether a decreased satiation response to food intake plays a role in the development of obesity is uncertain (48, 49) . Early satiation, defined as an inability to finish a normal size meal, has been linked to impaired fundic accommodation in some studies although not all studies agree and the association is controversial (50, 51) . For this reason, we investigated the association between obesity and the symptom early satiation; we speculated there would be more people with this symptom in those who were normal weight and less in the obese group. However, we did not observe increased reporting of early satiety in normal weight persons. This is contrary to previous observations in un-investigated subjects with obesity (16, 18) ; whether this reflects population or measurement differences is unknown.
Obesity is now considered to be a major health problem worldwide. Data from the National Center for Health Statistics show that 31% of the U.S. population of age 20 or above is clinically obese (BMI ≥ 30 Kg/m 2 ) (35) . The prevalence of obesity in Northern Sweden was less (16%) but still substantial; moreover, the rates of obesity in this cohort were only modestly higher than those reported across Sweden as a whole (10%) (52) . The present study had a number of other strengths. The ASQ is a reliable and adequately validated measure (25, 26) . The study was performed in the northern part of Sweden, but the population studied appears to be representative of the Swedish population in terms of most sociodemographic factors, and the response rates were excellent. The proportion with higher education was slightly lower in these communities and a low education was associated with a higher BMI, but education was controlled for in the analyses. Hospitalization and death from gastrointestinal disorders in the northern part of Sweden is similar to the rest of Sweden and the western world (31) . On the other hand, the impact of these GI symptoms on quality of life in obese versus non-obese was not assessed in this study. However, we did ask only about troublesome symptoms, implying the complaints reported were of importance to the community subjects.
In conclusion, in this population-based study, reflux symptoms were independently associated with BMI. Importantly, the association was explained by increased upper endoscopy findings in obesity.
